---
title: "Lishengpharma: Potassium Chloride Sustained-Release Tablets have passed the market approval application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254570443.md"
description: "Lishengpharma announced that the company has obtained the drug registration certificates for potassium chloride sustained-release tablets in specifications of 0.5g and 0.6g issued by the National Medical Products Administration, marking the approval of the drug for market licensing application. This drug is suitable for the treatment and prevention of hypokalemia, especially in cases where dietary management or reduced diuretic treatment is ineffective"
datetime: "2025-08-26T08:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254570443.md)
  - [en](https://longbridge.com/en/news/254570443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254570443.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/254570443.md) | [繁體中文](https://longbridge.com/zh-HK/news/254570443.md)


# Lishengpharma: Potassium Chloride Sustained-Release Tablets have passed the market approval application

According to the Zhitong Finance APP, Lishengpharma (002393.SZ) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the 0.5g specification of potassium chloride sustained-release tablets; and the "Drug Registration Certificate" for the 0.6g specification of potassium chloride sustained-release tablets. The above-mentioned drugs have passed the drug marketing license application.

The indications for potassium chloride sustained-release tablets are: for the treatment and prevention of hypokalemia with or without metabolic alkalosis, when dietary management with potassium-rich foods or reducing the dosage of diuretics is ineffective in these patients

### Related Stocks

- [Lishengpharma (002393.CN)](https://longbridge.com/en/quote/002393.CN.md)

## Related News & Research

- [Keyridge Asset Management Builds 6.96% Stake in Mincon Group](https://longbridge.com/en/news/278567970.md)
- [Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel](https://longbridge.com/en/news/278423327.md)
- [Pizu Group Details Tajikistan Mining Loan Deal and Planned 45% Stake in Kanzi Diyor](https://longbridge.com/en/news/278384508.md)
- [CATL and Rio Tinto target electrification of mining operations](https://longbridge.com/en/news/278348983.md)
- [Xiaomi bought back 3 million class B shares for HK$100 million on Mar 10, HKEX filing shows](https://longbridge.com/en/news/278546704.md)